Replies to post #256764 on Biotech Values

[dewophile]

re hep b, GSK@ JPM

"we now have a medicine that we are aiming at a 15-20% functional cure in the selected population"

current best therapy offers 1-2% functional cure, clearing SAg linked to almost 90% lower risk HCC and 60% lower risk all cause mortality